Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Cancer Therapy: Preclinical

Dual Kinase Inhibition of EGFR and HER2 Overcomes Resistance to Cetuximab in a Novel In Vivo Model of Acquired Cetuximab Resistance

Kelly M. Quesnelle and Jennifer R. Grandis
Kelly M. Quesnelle
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer R. Grandis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1078-0432.CCR-11-0370 Published September 2011
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Generation of a cetuximab resistance model in vivo. A, T24, CAL33, A431, OSC-19, SCC1, and SCC1c8 cells were used to generate xenografts in athymic nude mice (n = 6 for CAL33, A431, OSC-19, SCC1, and SCC1c8; n = 12 for T24) that were exposed to increasing concentrations of cetuximab by i.p. injection (0.8 mg 2×/wk increased to 1.0 mg 2×/wk and then increased to 0.8 mg 3×/wk; doses increased in nonresponsive xenografts only as indicated by arrows). Resistant tumor cells were then harvested and propagated in culture and (B) reinoculated to form xenografts that were treated with 0.8 mg 3×/wk immediately following tumor formation.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Validation of cetuximab resistance model in vitro and in vivo. A, xenografts were generated by subcutaneous inoculation of 1 million tumor cells in athymic nude mice (n = 7) from cetuximab-sensitive T24 or cetuximab-resistant T24PR3 cells and treated with cetuximab (2.0 mg 3×/wk by i.p. injection) immediately following tumor formation, generally at 7 to 10 days (**, P < 0.005). TUNEL staining was carried out on frozen, fixed tumors to detect apoptotic cells. Data shown are the average of cells counted in quadruplicate 20× fields of view for 2 tumors per cell type (*, P < 0.05). B, invasion studies were carried out with media containing either 1 μmol/L cetuximab or drug-free media. Invasion chambers were placed in the same media containing 10% FBS. After 24 hours, invading cells were stained and counted (**, P < 0.005). Data are the result of 2 independent experiments run in duplicate.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    611-CTF is hyperphosphorylated in cetuximab-resistant cells. A, cell lysates were collected under basal conditions when cells reached 70% confluence. Whole lysates were analyzed by Western blotting and probed for EGFR, HER2, and pHER2 (185 kDa) and 611-CTF and p611-CTF (110-kDa HER2 fragment). Densitometry is the result of 3 individual experiments where intensity of the p611-CTF bands was compared with the intensity of 611-CTF bands on the same gel (*, P < 0.05). A full image of these gels is available (Supplementary Fig. S1). B, cell lysates were collected under basal conditions when cells reached 70% confluence. Whole lysates were analyzed by Western blotting and probed for p-serine and cortactin. Densitometry is the result of 6 individual experiments where intensity of the p-serine bands for each cell type was compared with their respective cortactin bands from the same gel. Phosphorylation ratios for each cell line were compared with the T24 cell line for reference (*, P < 0.05).

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    A, T24PR3 cells were transduced with HER2 shRNA–containing lentiviral particles, and a representative image of the Western blots for full-length HER2 and 611-CTF from 4 clones and scramble control lysates are included here. Invasion studies in this figure were conducted as described earlier (*, P < 0.05), and all data are the result of 2 independent experiments run in duplicate. B, invasion studies were conducted using T24PR3 cells with media containing vehicle, cetuximab, trastuzumab to inhibit full-length HER2, or both cetuximab and trastuzumab. C, invasion studies were conducted using T24PR3 cells with media containing vehicle, cetuximab, the EGFR-HER2 kinase inhibitor afatinib, or both cetuximab and afatinib.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Dual kinase inhibition of EGFR and HER2 in vivo. Xenografts were created using cetuximab-resistant T24PR3 cells (A) or cetuximab-sensitive T24 cells (B) in athymic nude mice (n = 40). Mice were randomized on the basis of tumor volumes and treated with vehicle control, afatinib (0.4 mg daily by oral gavage), cetuximab (1.0 mg 3×/wk by i.p. injection), or both drugs concurrently for 21 days. Tumor volumes were measured 3 times per week for a total of 3 weeks. P values were generated using a Mann–Whitney test (*, P < 0.05). C, cell lysates were created from snap-frozen tumor tissue. Whole lysates were analyzed by Western blotting and probed for 611-CTF. Densitometry is the result of 4 technical replicates from 1 individual tumor of each treatment group normalized to the β-tubulin loading control for each tumor (*, P < 0.05; **, P < 0.005).

Additional Files

  • Figures
  • Supplementary Data

    Files in this Data Supplement:

    • Supplementary Figure 1 - PDF file - 166K
PreviousNext
Back to top
Clinical Cancer Research: 17 (18)
September 2011
Volume 17, Issue 18
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Dual Kinase Inhibition of EGFR and HER2 Overcomes Resistance to Cetuximab in a Novel In Vivo Model of Acquired Cetuximab Resistance
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Dual Kinase Inhibition of EGFR and HER2 Overcomes Resistance to Cetuximab in a Novel In Vivo Model of Acquired Cetuximab Resistance
Kelly M. Quesnelle and Jennifer R. Grandis
Clin Cancer Res September 15 2011 (17) (18) 5935-5944; DOI: 10.1158/1078-0432.CCR-11-0370

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Dual Kinase Inhibition of EGFR and HER2 Overcomes Resistance to Cetuximab in a Novel In Vivo Model of Acquired Cetuximab Resistance
Kelly M. Quesnelle and Jennifer R. Grandis
Clin Cancer Res September 15 2011 (17) (18) 5935-5944; DOI: 10.1158/1078-0432.CCR-11-0370
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Grant Support
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Targeting HER2 with Osimertinib in NSCLC
  • Combined VEGF/EGFR Inhibition
  • Radiotherapy with IDO1/PD-1 Blockade Treats Advanced GBM
Show more Cancer Therapy: Preclinical
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement